Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Epidemiology

Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

	Abstract	Full	Pdf
Nov 2021	673	653	221
Dec 2021	1103	1075	353
Jan 2022	489	487	158
Feb 2022	183	184	69
Mar 2022	214	209	93
Apr 2022	194	188	33
May 2022	134	134	40
Jun 2022	498	499	93
Jul 2022	231	235	56
Aug 2022	136	140	32
Sep 2022	131	137	49
Oct 2022	103	104	37
Nov 2022	104	104	25
Dec 2022	72	75	16
Jan 2023	86	87	29
Feb 2023	72	69	13
Mar 2023	71	67	27
Apr 2023	189	5	5
May 2023	104	5	4
Jun 2023	73	3	1
Jul 2023	80	8	2
Aug 2023	58	3	2
Sep 2023	94	11	3
Oct 2023	100	4	5
Nov 2023	95	14	4
Dec 2023	115	16	10
Jan 2024	111	13	9
Feb 2024	116	8	5
Mar 2024	113	18	4
Apr 2024	141	12	5
May 2024	88	12	4
Jun 2024	89	11	7
Jul 2024	111	11	2
Aug 2024	96	13	3
Total	6267	4614	1419